Bhatavdekar J M, Vora H H, Goyal A, Shah N G, Karelia N H, Trivedi S N
Tumori. 1987 Feb 28;73(1):59-63. doi: 10.1177/030089168707300112.
The efficiency of the combination of two tumor-associated antigens in recognising head and neck cancer was evaluated. The markers studied were CEA and ferritin by radioimmunoassay. CEA was estimated in 22 controls and 41 head and neck cancer patients. There was no difference in CEA values of controls and head and neck cancer patients, suggesting that CEA was not specific for head and neck malignancies. We measured serum ferritin in 27 controls and 58 patients with head and neck cancer. The mean ferritin level was significantly higher in patients (P less than 0.001) than in normal subjects. The ferritin level in patients with no evidence of clinical disease 8 months after treatment showed approximately normal levels, whereas the levels showed a tendency to increase or remain at high levels in patients with a poor prognosis, giving support to the contention that ferritin may prove to be a valuable adjunct in head and neck cancer.
评估了两种肿瘤相关抗原联合识别头颈癌的效率。通过放射免疫测定法研究的标志物为癌胚抗原(CEA)和铁蛋白。对22名对照者和41名头颈癌患者进行了CEA检测。对照者和头颈癌患者的CEA值没有差异,这表明CEA对头颈恶性肿瘤不具有特异性。我们对27名对照者和58名头颈癌患者进行了血清铁蛋白检测。患者的平均铁蛋白水平显著高于正常受试者(P<0.001)。治疗8个月后无临床疾病证据的患者铁蛋白水平显示大致正常,而预后较差的患者铁蛋白水平呈升高趋势或维持在高水平,这支持了铁蛋白可能成为头颈癌有价值辅助指标的观点。